Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy

Table 4

Survival analysis.

Variables		Survival			value
		2 yr (%)	4 yr (%)	Time (mth)
				Mean ± SE
General		99.2	98.0	53.53 ± 0.26	—
cT	1	99.3	99.3	53.75 ± 0.24	0.010
	2	99.0	99.0	52.59 ± 0.40
	3	100	66.7	41.66 ± 0.27
Age	<60	99.4	99.4	52.73 ± 0.27	0.313
	≥60	99.0	95.7	53.21 ± 0.54
Grade	1	98.8	95.7		0.537
	2	99.3	99.3
	3	100	100
Axillary intervention	SLNB	99.5	99.5		0.115
	SLNB + Axillary dx	98.2	90.0
	Axillary dx	100	100
Axillary dx	Yes	98.2	90.1	51.26 ± 1.91	0.039
	No	99.5	94.0	53.82 ± 0.17
SLNB status	Negative	99.4	94.5		0.114
	Z0011 applied	100	100
	Axillary dx	98.2	90
SLNB-positive and Z0011 status	Z0011 applied	100	100		0.450
	Z0011 not applied	98.2	90.0
pN	0	99.4	99.4		0.086
	1	100	91.7
	2	94.7	94.7
Adj. CT	No	99.2	99.2		0.609
	Yes	99.2	97.0

Yr : year; Mth : month; SLNB : sentinel lymph node biopsy; Dx : dissection; Adj. CT : adjuvant chemotherapy.